Shanghai Shen Lian Biomedical Corporation (SHA:688098)
China · Delayed Price · Currency is CNY 9.66
+0.06 (0.63%)
Feb 13, 2026, 3:00 PM CST
SHA:688098 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 291.32 | 301.93 | 300.14 | 327.87 | 357.79 | 337.39 |
Other Revenue | 1.48 | 1.48 | 1.34 | 0.72 | 0.64 | 0.34 |
| 292.81 | 303.41 | 301.49 | 328.59 | 358.43 | 337.73 | |
Revenue Growth (YoY) | -5.66% | 0.64% | -8.25% | -8.32% | 6.13% | 33.06% |
Cost of Revenue | 120.35 | 120.62 | 87.89 | 81.38 | 87.01 | 55.1 |
Gross Profit | 172.46 | 182.8 | 213.59 | 247.21 | 271.42 | 282.63 |
Selling, General & Admin | 138.04 | 155.91 | 134.72 | 128.69 | 120.97 | 123.35 |
Research & Development | 42.82 | 49.36 | 44.53 | 39.04 | 34.95 | 31.91 |
Other Operating Expenses | 1.97 | 2.76 | 3.54 | 3.43 | 3.57 | 2.97 |
Operating Expenses | 188.66 | 216.47 | 185.9 | 179.66 | 161.13 | 157.75 |
Operating Income | -16.2 | -33.67 | 27.7 | 67.56 | 110.29 | 124.88 |
Interest Expense | -0.22 | -0.02 | - | - | - | - |
Interest & Investment Income | 0.82 | 2.6 | 4.42 | 3.99 | 11.91 | 16.8 |
Currency Exchange Gain (Loss) | 0 | 0 | -0.02 | -0.05 | 0.01 | 0.04 |
Other Non Operating Income (Expenses) | 0.15 | -0.08 | -0.08 | -0.01 | 0.07 | -0 |
EBT Excluding Unusual Items | -15.45 | -31.17 | 32.02 | 71.49 | 122.29 | 141.72 |
Gain (Loss) on Sale of Investments | 1.45 | 0.88 | 2.35 | 0.35 | 1.78 | 0.75 |
Gain (Loss) on Sale of Assets | 0.02 | -0.25 | -0.4 | 0.14 | -0.6 | -0.05 |
Asset Writedown | -28.14 | -28.17 | - | -0.24 | - | - |
Other Unusual Items | 3.18 | 1.91 | 2.3 | 2.82 | 2.52 | 7.57 |
Pretax Income | -38.94 | -56.79 | 36.27 | 74.55 | 125.98 | 149.99 |
Income Tax Expense | -4.19 | -8.05 | 6.41 | 13.58 | 21.52 | 20.63 |
Earnings From Continuing Operations | -34.75 | -48.75 | 29.85 | 60.97 | 104.46 | 129.37 |
Minority Interest in Earnings | 4.41 | 4.01 | 1.67 | 0.13 | 5.74 | 0.15 |
Net Income | -30.34 | -44.74 | 31.52 | 61.1 | 110.2 | 129.51 |
Net Income to Common | -30.34 | -44.74 | 31.52 | 61.1 | 110.2 | 129.51 |
Net Income Growth | - | - | -48.42% | -44.55% | -14.91% | 66.14% |
Shares Outstanding (Basic) | 411 | 407 | 394 | 407 | 408 | 405 |
Shares Outstanding (Diluted) | 411 | 407 | 394 | 407 | 408 | 418 |
Shares Change (YoY) | -6.19% | 3.23% | -3.28% | -0.20% | -2.31% | 12.54% |
EPS (Basic) | -0.07 | -0.11 | 0.08 | 0.15 | 0.27 | 0.32 |
EPS (Diluted) | -0.07 | -0.11 | 0.08 | 0.15 | 0.27 | 0.31 |
EPS Growth | - | - | -46.67% | -44.44% | -12.90% | 47.62% |
Free Cash Flow | -15.28 | 4.45 | -126.11 | -84.04 | -98.04 | -51.83 |
Free Cash Flow Per Share | -0.04 | 0.01 | -0.32 | -0.21 | -0.24 | -0.12 |
Dividend Per Share | - | - | 0.035 | 0.080 | - | 0.100 |
Dividend Growth | - | - | -56.25% | - | - | 25.00% |
Gross Margin | 58.90% | 60.25% | 70.85% | 75.23% | 75.72% | 83.69% |
Operating Margin | -5.53% | -11.10% | 9.19% | 20.56% | 30.77% | 36.98% |
Profit Margin | -10.36% | -14.75% | 10.45% | 18.59% | 30.75% | 38.35% |
Free Cash Flow Margin | -5.22% | 1.47% | -41.83% | -25.57% | -27.35% | -15.35% |
EBITDA | 55.13 | 34.15 | 90.85 | 124.49 | 153.91 | 145.63 |
EBITDA Margin | 18.83% | 11.25% | 30.13% | 37.89% | 42.94% | 43.12% |
D&A For EBITDA | 71.33 | 67.82 | 63.15 | 56.94 | 43.62 | 20.75 |
EBIT | -16.2 | -33.67 | 27.7 | 67.56 | 110.29 | 124.88 |
EBIT Margin | -5.53% | -11.10% | 9.19% | 20.56% | 30.77% | 36.98% |
Effective Tax Rate | - | - | 17.69% | 18.21% | 17.08% | 13.75% |
Revenue as Reported | 292.81 | 303.41 | 301.49 | - | 358.43 | 337.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.